Loading stock data…
CG Oncology, Inc. (CGON)
$69.32-1.80 (-2.53%)
Market ClosedLast close Jul 24
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CG Oncology, Inc. in the Healthcare sector is trading at $69.32 with a market capitalization of $6.5B. Wall Street consensus targets $90.69 (13 analysts), implying a +30.8% move over the next 12 months. The stock is currently near its 52-week high of $77.00, remaining 23.7% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +30.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.08M↓ | $2.32M↑ | $1.67M | $0↓ | $52,000 |
| Gross Profit | -$1.88M↓ | -$748,000↓ | $89,000 | — | $52,000 |
| Operating Income | -$66.39M↓ | -$48.70M↑ | -$51.13M↓ | -$48.74M↓ | -$42.20M |
| Net Income | -$60.20M↓ | -$41.31M↑ | -$43.81M↓ | -$41.43M↓ | -$34.45M |
Peer Comparison
JNJUNHPFE
Fundamentals
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigationa...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.50B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.31
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-17.10%
Volume
Today's trading volume
351,318
Recent News
CG Oncology Stock Gains 12% in Three Months: What's Driving It?
CGON climbs as cretostimogene nears a planned 2026 BLA filing, posts encouraging phase II data. It maintains a cash position that supports operations through 2029.
Big Insider Buying Puts These 2 Stocks on the Radar
Every investor is looking for opportunities, but finding promising stocks and deciding when to buy is rarely a simple task. Successful investing often depends on separating temporary market moves from businesses that offer meaningful long-term value.Claim 55% Off TipRanks Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks O
CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead
CG Oncology (NASDAQ:CGON) Chief Executive Officer Arthur outlined the company’s upcoming clinical and regulatory milestones for cretostimogene during a presentation at the Goldman Sachs Global Healthcare Conference, emphasizing data readouts, a potential filing and commercial preparation in non-musc
CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push
CG Oncology (NASDAQ:CGON) is focused on advancing cretostimogene, an oncolytic immunotherapy for non-muscle invasive bladder cancer, Chief Executive Officer Arthur Kuan said during a discussion at the Jefferies Global Healthcare Conference in New York. Kuan said the company believes the therapy cou
Did CG Oncology’s Leadership Consolidation Around CEO Kuan Just Shift CGON’s Commercialization Narrative?
CG Oncology, Inc. has agreed to the separation of President & Chief Operating Officer Ambaw Bellete effective June 30, 2026, while appointing CEO Arthur Kuan as President and launching a search for a Chief Commercial Officer. This consolidation of leadership roles around Kuan, alongside an active search for commercial expertise, highlights a meaningful shift in how CG Oncology plans to manage execution and commercialization priorities. We’ll now examine how this leadership transition,...